GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » 3-Year EPS without NRI Growth Rate

Ono Pharmaceutical Co (Ono Pharmaceutical Co) 3-Year EPS without NRI Growth Rate : 24.90% (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co 3-Year EPS without NRI Growth Rate?

Ono Pharmaceutical Co's EPS without NRI for the three months ended in Dec. 2023 was $0.18.

During the past 12 months, Ono Pharmaceutical Co's average EPS without NRI Growth Rate was 15.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was 24.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 34.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Ono Pharmaceutical Co was 170.60% per year. The lowest was -53.00% per year. And the median was 3.45% per year.


Competitive Comparison of Ono Pharmaceutical Co's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ono Pharmaceutical Co's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Ono Pharmaceutical Co's 3-Year EPS without NRI Growth Rate falls into.



Ono Pharmaceutical Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Ono Pharmaceutical Co  (OTCPK:OPHLY) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Ono Pharmaceutical Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Ono Pharmaceutical Co (Ono Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564
Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Headlines